Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2826
Ceco Environmental
CECO
$3.86B
| $566K | ﹤0.01% |
85,898
-28,200
| -25% | -$153K |
2015 Q1
21 quarters
|
|
2827
PJT Partners
PJT
$3.51B
| $565K | ﹤0.01% |
+11,000
| New | +$542K |
2020 Q2
0 quarters
|
|
|
NEOS
2828
DELISTED
Neos Therapeutics, Inc
NEOS
| $564K | ﹤0.01% |
823,143
+121,900
| +17% | +$96.6K |
2019 Q1
5 quarters
|
|
2829
ZK International Group
ZKIN
$107M
| $559K | ﹤0.01% |
56,410
-786
| -1% | -$6.64K |
2018 Q4
6 quarters
|
|
|
SHLO
2830
DELISTED
Shiloh Industries Inc
SHLO
| $559K | ﹤0.01% |
345,211
+5,406
| +2% | +$5.99K |
2016 Q3
15 quarters
|
|
2831
China Pharma Holdings
CPHI
$37.5M
| $558K | ﹤0.01% |
1,676
-224
| -12% | -$55.3K |
2013 Q2
28 quarters
|
|
2832
Vanguard Morningstar Mega Cap Growth ETF
MGK
$35.2B
| $556K | ﹤0.01% |
17,000
-14,500
| -46% | -$433K |
2019 Q4
2 quarters
|
|
|
OPOF
2833
DELISTED
Old Point Financial
OPOF
| $556K | ﹤0.01% |
36,463
+1,122
| +3% | +$17.5K |
2017 Q2
12 quarters
|
|
2834
Babcock & Wilcox
BW
$813M
| $554K | ﹤0.01% |
242,888
-63,562
| -21% | -$110K |
2019 Q1
5 quarters
|
|
2835
CubeSmart
CUBE
$8.55B
| $553K | ﹤0.01% |
20,500
-428,211
| -95% | -$11.3M |
2017 Q4
10 quarters
|
|
2836
iShares ESG Aware MSCI USA ETF
ESGU
$18.3B
| $553K | ﹤0.01% |
+7,900
| New | +$520K |
2020 Q2
0 quarters
|
|
|
TTPH
2837
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $552K | ﹤0.01% |
219,140
-20,800
| -9% | -$39.4K |
2015 Q4
18 quarters
|
|
|
ALIM
2838
DELISTED
Alimera Sciences
ALIM
| $549K | ﹤0.01% |
87,104
+11,100
| +15% | +$58K |
2017 Q2
12 quarters
|
|
2839
Cogent Biosciences
COGT
$5.38B
| $548K | ﹤0.01% |
297,851
+231,950
| +352% | +$430K |
2018 Q3
7 quarters
|
|
2840
Scully Royalty
SRL
$77.7M
| $548K | ﹤0.01% |
72,170
+6,500
| +10% | +$51.1K |
2013 Q2
28 quarters
|
|
|
LUB
2841
DELISTED
Luby's Inc.
LUB
| $548K | ﹤0.01% |
377,927
+30,800
| +9% | +$30.7K |
2014 Q4
22 quarters
|
|
|
TULP
2842
Bloomia Holdings
TULP
| $546K | ﹤0.01% |
109,198
+600
| +0.6% | +$2.99K |
2013 Q2
28 quarters
|
|
|
MBAI
2843
MBody AI Ltd. Ordinary Share
MBAI
$49.7M
| $545K | ﹤0.01% |
6,522
+4,305
| +194% | +$381K |
2017 Q3
11 quarters
|
|
|
ORKA
2844
Oruka Therapeutics
ORKA
$5.44B
| $545K | ﹤0.01% |
6,857
-4,251
| -38% | -$278K |
2016 Q4
14 quarters
|
|
|
TCON
2845
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $544K | ﹤0.01% |
13,870
+2,284
| +20% | +$90.4K |
2016 Q3
15 quarters
|
|
2846
Xtrackers MSCI EAFE Hedged Equity ETF
DBEF
$9.23B
| $541K | ﹤0.01% |
+17,900
| New | +$519K |
2020 Q2
0 quarters
|
|
|
MRIN
2847
DELISTED
Marin Software
MRIN
| $541K | ﹤0.01% |
63,479
+4,586
| +8% | +$40.2K |
2015 Q1
21 quarters
|
|
2848
IZEA Worldwide
IZEA
$40.1M
| $539K | ﹤0.01% |
+118,218
| New | +$331K |
2020 Q2
0 quarters
|
|
2849
Virco
VIRC
$102M
| $538K | ﹤0.01% |
205,269
-3,800
| -2% | -$9.38K |
2013 Q2
28 quarters
|
|
|
FRGI
2850
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
| $538K | ﹤0.01% |
84,400
-16,100
| -16% | -$112K |
2018 Q3
7 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.